Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (
NASDAQ:DYN ), focused on developing therapies for ...
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.
Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.
Why Avidity Biosciences Zoomed to a 12% Gain This Week The company's most promising pipeline program can continue unabated.
